Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Hsu

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Arthritis Care & Research|May 28, 2010
Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trialAtul Deodhar, Jürgen Braun, Robert D Inman, et al.
Annals of the Rheumatic Diseases|August 24, 2012
MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitorPedro Machado, Robert B M Landewé, Jürgen Braun, et al.
Annals of the Rheumatic Diseases|February 28, 2018
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 studyPeter C Taylor, Michael H Schiff, Qingmin Wang, et al.
RMD Open|February 2, 2021
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)Daniel Aletaha, Clifton O Bingham, George Athanasios Karpouzas, et al.
Annals of the Rheumatic Diseases|May 7, 2013
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trialJürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Arthritis and Rheumatism|January 13, 2012
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitisElizabeth C Hsia, Neil Schluger, John J Cush, et al.
Annals of the Rheumatic Diseases|December 1, 2011
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE studyJürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Brain, Behavior, and Immunity|July 6, 2017
The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's diseaseYu Sun, Dai Wang, Giacomo Salvadore, et al.
Arthritis and Rheumatism|November 1, 2008
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trialRobert D Inman, John C Davis, Désirée van der Heijde, et al.
Molecular Psychiatry|August 21, 2019
Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disordersGayle M Wittenberg, Annie Stylianou, Yun Zhang, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Arthritis Care & Research|May 28, 2010
Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trialAtul Deodhar, Jürgen Braun, Robert D Inman, et al.
Annals of the Rheumatic Diseases|August 24, 2012
MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitorPedro Machado, Robert B M Landewé, Jürgen Braun, et al.
Annals of the Rheumatic Diseases|February 28, 2018
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 studyPeter C Taylor, Michael H Schiff, Qingmin Wang, et al.
RMD Open|February 2, 2021
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)Daniel Aletaha, Clifton O Bingham, George Athanasios Karpouzas, et al.
Annals of the Rheumatic Diseases|May 7, 2013
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trialJürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Arthritis and Rheumatism|January 13, 2012
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitisElizabeth C Hsia, Neil Schluger, John J Cush, et al.
Annals of the Rheumatic Diseases|December 1, 2011
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE studyJürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Brain, Behavior, and Immunity|July 6, 2017
The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's diseaseYu Sun, Dai Wang, Giacomo Salvadore, et al.
Arthritis and Rheumatism|November 1, 2008
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trialRobert D Inman, John C Davis, Désirée van der Heijde, et al.
Molecular Psychiatry|August 21, 2019
Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disordersGayle M Wittenberg, Annie Stylianou, Yun Zhang, et al.
Pageof 5